Diabetic cardiomyopathy

Omar Asghar, Ahmed Al-Sunni, Kaivan Khavandi, Ali Khavandi, Sarah Withers, Adam Greenstein, Anthony M. Heagerty, Rayaz Malik

Research output: Contribution to journalReview article

118 Citations (Scopus)

Abstract

Diabetic cardiomyopathy is a distinct primary disease process, independent of coronary artery disease, which leads to heart failure in diabetic patients. Epidemiological and clinical trial data have confirmed the greater incidence and prevalence of heart failure in diabetes. Novel echocardiographic and MR (magnetic resonance) techniques have enabled a more accurate means of phenotyping diabetic cardiomyopathy. Experimental models of diabetes have provided a range of novel molecular targets for this condition, but none have been substantiated in humans. Similarly, although ultrastructural pathology of the microvessels and cardiomyocytes is well described in animal models, studies in humans are small and limited to light microscopy. With regard to treatment, recent data with thiazoledinediones has generated much controversy in terms of the cardiac safety of both these and other drugs currently in use and under development. Clinical trials are urgently required to establish the efficacy of currently available agents for heart failure, as well as novel therapies in patients specifically with diabetic cardiomyopathy.

Original languageEnglish
Pages (from-to)741-760
Number of pages20
JournalClinical Science
Volume116
Issue number10
DOIs
Publication statusPublished - May 2009
Externally publishedYes

Fingerprint

Diabetic Cardiomyopathies
Heart Failure
Clinical Trials
Microvessels
Cardiac Myocytes
Coronary Artery Disease
Microscopy
Theoretical Models
Magnetic Resonance Spectroscopy
Animal Models
Pathology
Safety
Light
Incidence
Therapeutics
Pharmaceutical Preparations

Keywords

  • Diabetic cardiomyopathy
  • Heart failure
  • Hyperglycaemia
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Asghar, O., Al-Sunni, A., Khavandi, K., Khavandi, A., Withers, S., Greenstein, A., ... Malik, R. (2009). Diabetic cardiomyopathy. Clinical Science, 116(10), 741-760. https://doi.org/10.1042/CS20080500

Diabetic cardiomyopathy. / Asghar, Omar; Al-Sunni, Ahmed; Khavandi, Kaivan; Khavandi, Ali; Withers, Sarah; Greenstein, Adam; Heagerty, Anthony M.; Malik, Rayaz.

In: Clinical Science, Vol. 116, No. 10, 05.2009, p. 741-760.

Research output: Contribution to journalReview article

Asghar, O, Al-Sunni, A, Khavandi, K, Khavandi, A, Withers, S, Greenstein, A, Heagerty, AM & Malik, R 2009, 'Diabetic cardiomyopathy', Clinical Science, vol. 116, no. 10, pp. 741-760. https://doi.org/10.1042/CS20080500
Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A et al. Diabetic cardiomyopathy. Clinical Science. 2009 May;116(10):741-760. https://doi.org/10.1042/CS20080500
Asghar, Omar ; Al-Sunni, Ahmed ; Khavandi, Kaivan ; Khavandi, Ali ; Withers, Sarah ; Greenstein, Adam ; Heagerty, Anthony M. ; Malik, Rayaz. / Diabetic cardiomyopathy. In: Clinical Science. 2009 ; Vol. 116, No. 10. pp. 741-760.
@article{cf9edcc472b14c29b0003801c69238ab,
title = "Diabetic cardiomyopathy",
abstract = "Diabetic cardiomyopathy is a distinct primary disease process, independent of coronary artery disease, which leads to heart failure in diabetic patients. Epidemiological and clinical trial data have confirmed the greater incidence and prevalence of heart failure in diabetes. Novel echocardiographic and MR (magnetic resonance) techniques have enabled a more accurate means of phenotyping diabetic cardiomyopathy. Experimental models of diabetes have provided a range of novel molecular targets for this condition, but none have been substantiated in humans. Similarly, although ultrastructural pathology of the microvessels and cardiomyocytes is well described in animal models, studies in humans are small and limited to light microscopy. With regard to treatment, recent data with thiazoledinediones has generated much controversy in terms of the cardiac safety of both these and other drugs currently in use and under development. Clinical trials are urgently required to establish the efficacy of currently available agents for heart failure, as well as novel therapies in patients specifically with diabetic cardiomyopathy.",
keywords = "Diabetic cardiomyopathy, Heart failure, Hyperglycaemia, Type 2 diabetes",
author = "Omar Asghar and Ahmed Al-Sunni and Kaivan Khavandi and Ali Khavandi and Sarah Withers and Adam Greenstein and Heagerty, {Anthony M.} and Rayaz Malik",
year = "2009",
month = "5",
doi = "10.1042/CS20080500",
language = "English",
volume = "116",
pages = "741--760",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "10",

}

TY - JOUR

T1 - Diabetic cardiomyopathy

AU - Asghar, Omar

AU - Al-Sunni, Ahmed

AU - Khavandi, Kaivan

AU - Khavandi, Ali

AU - Withers, Sarah

AU - Greenstein, Adam

AU - Heagerty, Anthony M.

AU - Malik, Rayaz

PY - 2009/5

Y1 - 2009/5

N2 - Diabetic cardiomyopathy is a distinct primary disease process, independent of coronary artery disease, which leads to heart failure in diabetic patients. Epidemiological and clinical trial data have confirmed the greater incidence and prevalence of heart failure in diabetes. Novel echocardiographic and MR (magnetic resonance) techniques have enabled a more accurate means of phenotyping diabetic cardiomyopathy. Experimental models of diabetes have provided a range of novel molecular targets for this condition, but none have been substantiated in humans. Similarly, although ultrastructural pathology of the microvessels and cardiomyocytes is well described in animal models, studies in humans are small and limited to light microscopy. With regard to treatment, recent data with thiazoledinediones has generated much controversy in terms of the cardiac safety of both these and other drugs currently in use and under development. Clinical trials are urgently required to establish the efficacy of currently available agents for heart failure, as well as novel therapies in patients specifically with diabetic cardiomyopathy.

AB - Diabetic cardiomyopathy is a distinct primary disease process, independent of coronary artery disease, which leads to heart failure in diabetic patients. Epidemiological and clinical trial data have confirmed the greater incidence and prevalence of heart failure in diabetes. Novel echocardiographic and MR (magnetic resonance) techniques have enabled a more accurate means of phenotyping diabetic cardiomyopathy. Experimental models of diabetes have provided a range of novel molecular targets for this condition, but none have been substantiated in humans. Similarly, although ultrastructural pathology of the microvessels and cardiomyocytes is well described in animal models, studies in humans are small and limited to light microscopy. With regard to treatment, recent data with thiazoledinediones has generated much controversy in terms of the cardiac safety of both these and other drugs currently in use and under development. Clinical trials are urgently required to establish the efficacy of currently available agents for heart failure, as well as novel therapies in patients specifically with diabetic cardiomyopathy.

KW - Diabetic cardiomyopathy

KW - Heart failure

KW - Hyperglycaemia

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=67649285971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649285971&partnerID=8YFLogxK

U2 - 10.1042/CS20080500

DO - 10.1042/CS20080500

M3 - Review article

C2 - 19364331

AN - SCOPUS:67649285971

VL - 116

SP - 741

EP - 760

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 10

ER -